Kestra Medical Technologies (NASDAQ:KMTS) Insider Sells $342,000.00 in Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Brian Daniel Webster sold 15,000 shares of the company’s stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $22.80, for a total value of $342,000.00. Following the sale, the insider owned 394,786 shares of the company’s stock, valued at approximately $9,001,120.80. The trade was a 3.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Brian Daniel Webster also recently made the following trade(s):

• On Monday, December 29th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $26.59, for a total value of $398,850.00.

Kestra Medical Technologies Trading Down 0.6%

KMTS opened at $22.85 on Tuesday. The stock has a market capitalization of $1.33 billion and a price-to-earnings ratio of -7.21. The company has a quick ratio of 5.47, a current ratio of 5.47 and a debt-to-equity ratio of 0.26. Kestra Medical Technologies, Ltd. has a twelve month low of $13.25 and a twelve month high of $30.00. The company has a 50-day simple moving average of $25.63 and a 200 day simple moving average of $22.16.

Analysts Set New Price Targets

A number of research analysts recently issued reports on KMTS shares. The Goldman Sachs Group set a $24.00 price objective on shares of Kestra Medical Technologies in a research note on Friday. Piper Sandler lifted their price target on Kestra Medical Technologies from $27.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, December 12th. BTIG Research began coverage on Kestra Medical Technologies in a report on Tuesday, November 18th. They set a “buy” rating and a $32.00 price target for the company. Stifel Nicolaus set a $30.00 target price on Kestra Medical Technologies in a research report on Friday, December 12th. Finally, Wells Fargo & Company lifted their price target on shares of Kestra Medical Technologies from $27.00 to $28.00 and gave the company an “overweight” rating in a report on Friday, December 12th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $29.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. bought a new position in Kestra Medical Technologies in the 3rd quarter valued at approximately $48,000. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Kestra Medical Technologies during the second quarter worth $54,000. BNP Paribas Financial Markets grew its stake in shares of Kestra Medical Technologies by 148.9% in the third quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock worth $65,000 after purchasing an additional 1,638 shares during the last quarter. Brown Brothers Harriman & Co. raised its position in shares of Kestra Medical Technologies by 26.8% during the third quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock worth $74,000 after acquiring an additional 656 shares during the last quarter. Finally, New York State Common Retirement Fund bought a new stake in shares of Kestra Medical Technologies in the 2nd quarter valued at $93,000.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.